Johnson & Johnson and Compass Pathways Submit Applications for Advanced Psychedelic…
What happened
Johnson & Johnson and Compass Pathways submitted applications to U.S. regulators regarding the advanced psychedelic therapy market on September 21, 2026. The applications concern COMP360, a synthetic compound derived from mushroom species. Compass Pathways has been gradually submitting these applications with U.S. regulators and expects to complete the filing in the fourth quarter.
From biopharmadive.com
Why it matters
The market infrastructure for these therapies has evolved significantly since the introduction of ketamine-based treatments. That precedent has led to the rise of thousands of interventional psychiatry clinics across the U.S., which may serve as future testing grounds for psychedelic therapies.
From biopharmadive.com
Who's involved
- Johnson & JohnsonU.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer involved in the market.
- Compass PathwaysMental health care company developing the synthetic psychedelic compound COMP360.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Compass PathwaysSpeculative
The filing could move closer to market approval and revenue generation for Compass Pathways.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Compass Pathways
mental health care company
Nothing else this week.